Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.30 Exhibit 10.30
- 10.31 Exhibit 10.31
- 10.32 Exhibit 10.32
- 10.33 Exhibit 10.33
- 10.34 Exhibit 10.34
- 10.35 Exhibit 10.35
- 10.36 Exhibit 10.36
- 10.37 Exhibit 10.37
- 10.38 Exhibit 10.38
- 10.39 Exhibit 10.39
- 10.40 Exhibit 10.40
- 16.1 Exhibit 16.1
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- EX-FILING FEES Filing Fees Table
- Download Excel data file
- View Excel data file
Associated filings
- 5 Dec 22 424B3 Prospectus supplement
- 14 Nov 22 EFFECT Notice of effectiveness
- 10 Nov 22 424B3 Prospectus supplement
- 4 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 24 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
29 Aug 22 S-4 Registration of securities issued in business combination transactions
KANT similar filings
- 4 Nov 22 Registration of securities issued in business combination transactions (amended)
- 24 Oct 22 Registration of securities issued in business combination transactions (amended)
- 3 Oct 22 Registration of securities issued in business combination transactions (amended)
- 29 Aug 22 Registration of securities issued in business combination transactions
- 6 Nov 20 Registration of securities issued in business combination transactions (amended)
- 28 Oct 20 Registration of securities issued in business combination transactions (amended)
- 23 Sep 20 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.12
CONSENT OF PERSON NAMED TO BECOME A DIRECTOR
Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to being named as a director nominee and to the disclosure of the undersigned’s biographical information included in the Registration Statement on Form S-4, and any amendments thereto, to be filed by Yumanity Therapeutics, Inc. with the Securities and Exchange Commission. The undersigned further consents to the filing of this consent as an exhibit to such Registration Statement.
/s/ David Arkowitz | ||
Name: | David Arkowitz | |
Date: | August 26, 2022 |